Endo International (NSDQ:ENDP) posted a net loss in the second quarter of this year, citing charges like the $775 million it has set aside to resolve 22,000 remaining lawsuits relating to the company’s vaginal-mesh implants.
The generic drugmaker faced other setbacks this quarter, including the FDA asking that Endo pull its painkiller, Opana ER, from the market. The regulatory watchdog said that the benefits of the abuse-deterrent drug no longer outweigh the risks.
Get the full story at our sister site, Drug Delivery Business News.
The post Endo swings to Q2 loss on $775m pelvic mesh set-aside appeared first on MassDevice.